益得生物科技股份有限公司
益得生物科技股份有限公司（Intech Biopharm Corporation）在台灣及國際市場研發製造治療呼吸道疾病之學名藥。公司擁有 iLEF（低乙醇含量定量噴霧吸入劑）技術平台，用於氣喘與慢性阻塞性肺病（COPD）藥物開發。產品品牌包括 Synflutide、Duasma、Synvent 等。公司成立於 2010 年，總部位於台灣台北。
該股 RSI(6) 為 57.0，處於中性區間，短線無明顯超買超賣訊號。股價站上20日、60日、120日均線，跌破5日均線。短中期均線呈多頭排列，趨勢偏多。KD 指標中性（K=29.2）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -4 | 0 | 0 | -4 |
| 09-23 | 0 | 0 | +4 | 0 |
| 09-22 | -20 | 0 | 0 | -20 |
| 09-21 | -6 | 0 | +1 | -5 |
| 09-18 | +3 | 0 | +3 | +2 |
| 09-17 | -25 | 0 | +1 | -24 |
| 09-16 | -1 | 0 | 0 | -1 |
| 09-15 | -1 | 0 | +2 | -1 |
| 09-14 | -8 | 0 | 0 | -8 |
| 09-11 | -13 | 0 | +2 | -12 |
| 09-10 | -22 | 0 | +8 | -23 |
| 09-09 | -28 | 0 | +6 | -27 |
| 09-01 | -16 | 0 | 0 | -16 |
| 08-31 | -31 | 0 | 0 | -32 |
| 08-28 | +2 | 0 | 0 | +2 |
| 08-27 | +7 | 0 | +2 | +7 |
| 08-26 | +19 | 0 | +1 | +19 |
| 08-25 | -3 | 0 | +3 | -3 |
| 08-24 | -68 | 0 | +6 | -68 |
| 08-21 | -86 | 0 | +10 | -86 |
| 08-20 | -14 | 0 | +10 | -14 |
| 08-19 | 0 | 0 | 0 | 0 |
| 08-18 | -1 | 0 | 0 | -1 |
| 08-17 | -7 | 0 | 0 | -7 |
| 08-14 | -2 | 0 | 0 | -2 |
| 08-13 | -6 | 0 | +12 | -6 |
| 08-12 | +8 | 0 | 0 | +8 |
| 08-11 | -26 | 0 | 0 | -26 |
| 08-10 | +3 | 0 | +10 | +3 |
| 08-07 | -11 | 0 | 0 | -11 |
| 08-06 | -6 | 0 | 0 | -6 |
| 08-05 | +32 | 0 | 0 | +32 |
| 08-04 | +42 | 0 | 0 | +42 |
| 08-03 | +25 | 0 | 0 | +25 |
| 07-31 | +1 | 0 | 0 | +1 |
| 07-30 | -33 | 0 | +2 | -33 |
| 07-29 | +22 | 0 | 0 | +22 |
| 07-28 | +25 | 0 | 0 | +25 |
| 07-27 | +29 | 0 | 0 | +29 |
| 07-24 | +25 | 0 | +14 | +26 |
| 07-23 | +64 | 0 | 0 | +64 |
| 07-22 | -3 | 0 | 0 | -3 |
| 07-21 | -23 | 0 | 0 | -23 |
| 07-20 | +7 | 0 | 0 | +7 |
| 07-17 | -38 | 0 | 0 | -38 |
| 07-16 | +10 | 0 | 0 | +10 |
| 07-15 | +9 | 0 | 0 | +9 |
| 07-14 | -26 | 0 | 0 | -26 |
| 07-13 | +1 | 0 | 0 | +1 |
| 07-09 | -8 | 0 | 0 | -8 |
| 07-08 | +26 | 0 | 0 | +26 |
| 07-07 | +27 | 0 | +1 | +27 |
| 07-06 | -9 | 0 | +1 | -10 |
| 07-03 | -40 | 0 | 0 | -40 |
| 07-02 | +29 | 0 | 0 | +29 |
| 07-01 | -12 | 0 | 0 | -12 |
| 06-30 | +11 | 0 | 0 | +11 |
| 06-29 | -1 | 0 | 0 | -1 |
| 06-26 | -11 | 0 | 0 | -11 |
| 06-25 | +13 | 0 | 0 | +13 |
| 06-24 | +30 | 0 | +2 | +31 |
| 06-23 | -40 | 0 | 0 | -40 |
| 06-22 | -14 | 0 | +2 | -14 |
| 06-18 | -8 | 0 | +2 | -8 |
| 06-17 | -10 | 0 | 0 | -10 |
| 06-16 | -25 | 0 | +2 | -25 |
| 06-15 | 0 | 0 | +2 | 0 |
| 06-12 | +1 | 0 | 0 | 0 |
| 06-11 | -48 | 0 | +2 | -48 |
| 06-10 | -30 | 0 | 0 | -30 |
| 06-09 | +19 | 0 | 0 | +19 |
| 06-08 | -12 | 0 | 0 | -12 |
| 06-05 | +52 | 0 | 0 | +43 |
| 06-04 | 0 | 0 | +2 | 0 |
| 06-03 | -262 | 0 | +2 | -263 |
| 06-02 | -21 | 0 | +3 | -21 |
| 06-01 | +75 | 0 | 0 | +75 |
| 05-29 | +143 | 0 | 0 | +143 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/04 | 556 萬 | -35.5% | +43.7% |
| 2026/03 | 862 萬 | +436.2% | +2527.1% |
| 2026/02 | 161 萬 | -78.3% | -72.5% |
| 2026/01 | 739 萬 | +169.9% | +394.2% |
| 2025/12 | 274 萬 | +413.9% | -56.6% |
| 2025/11 | 53 萬 | -65.7% | -84.1% |
| 2025/10 | 155 萬 | -74.6% | +4.4% |
| 2025/09 | 610 萬 | +1198.1% | +22496.3% |
| 2025/08 | 47 萬 | -33.7% | -91.2% |
| 2025/07 | 71 萬 | -99.0% | -78.3% |
| 2025/06 | 7046 萬 | +424.5% | +8430.9% |
| 2025/05 | 1344 萬 | - | +679.7% |